COVID-19 vaccination in mainland China

Last updated

COVID-19 vaccination in mainland China
Chart of COVID-19 vaccine doses administered in Mainland China.png
COVID-19 vaccine doses administered in mainland China.
Date22 July 2020 (2020-07-22) – present
LocationFlag of the People's Republic of China.svg  China
Cause COVID-19 pandemic in mainland China
TargetImmunization against COVID-19
Organized by Joint Prevention and Control Mechanism in Response to the COVID-19 Pandemic of the State Council  [ zh ]
(headquartered at National Health Commission)
Participants2,482,895,000 [1] (total doses administered)
(As of 25 November 2021)
Outcome1,225,000,000 [1] (total vaccinated)
(As of 25 November 2021)
1,076,308,000 [1] (fully vaccinated)
(As of 25 November 2021)

COVID-19 vaccination in mainland China is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mainland China, in response to the ongoing pandemic in the region.

Contents

Administration

On June 2020, the Sinopharm BIBP vaccine (BBIBP-CorV) was authorized for emergency use in China. On July 22, Chinese authorities started the emergency use of COVID-19 vaccines. [2]

On December 15, 2020, the COVID-19 vaccination for people under high risk started in China. [3] On December 19, 2020, the National Health Commission (NHC) said that there has been 1 million doses of COVID-19 vaccine administered in China as of the day, and no serious adverse reactions were observed. [4]

On December 31, 2020, NHC announced that the Sinopharm BIBP vaccine has been approved through the conditional marketing authorization process, and more than 3 million doses of COVID-19 vaccine has been administered in China. [5] At the same time, NHC declares that COVID-19 vaccination is free to Chinese citizens. [6]

On January 27, 2021, NHC said that the vaccination is being carried out in order, and there has been 22.767 million doses of COVID-19 vaccine administered in China as of January 26. [7]

On March 1, 2021, Zhong Nanshan said that the vaccination rate of COVID-19 vaccine in China was currently 3.56%, and the Chinese Center for Disease Control and Prevention hoped the rate reach 40% by the end of June 2021. [8]

Since late March of 2021, the autorities has accelerated the promotion of free COVID-19 vaccination for the whole population. [3] On March 22, 2021, Sun Chunlan, the Vice Premier of the State Council, stated that COVID-19 vaccination in China should be accelerated and the vaccination rate should be increased. [9] On March 24, 2021, NHC announced that the number doses of COVID-19 vaccine administered will be daily reported on its website and social media account since that day. [10] On March 29, 2021, NHC released the first version of the COVID-19 Vaccine Technology Guide. [11]

On April 21, 2021, NHC stated that more that 200 million doses of COVID-19 vaccine has been administered in China, and 80% of doctors and nurses has been vaccinated. [12]

On May 14, 2021, NHC restated that the COVID-19 administration progress should be accelerated due to the proportion of mutated SARS-CoV-2 and the re-appearance of local cases. [13]

On June 19, 2021, NHC announced that more than 1.01489 billion doses of COVID-19 vaccine has been administered in China. [14]

Doses of COVID-19 vaccine administrated in mainland China
As ofDoses administrated
(in million)
References
Dec 19
(2020)
>1 [4]
Dec 31
(2020)
>3 [5]
Jan 27
(2021)
22.767 [7]
Feb 940.52 [15]
Mar 1564.98 [16]
Mar 28102.417 [DR 1]
Apr 21204.191 [DR 2]
May 7308.226 [DR 3]
May 16406.938 [DR 4]
May 23510.858 [DR 5]
May 28602.991 [DR 6]
Jun 2704.826 [DR 7]
Jun 8808.962 [DR 8]
Jun 14904.134 [DR 9]
Jun 191,010.489 [DR 10]
Jun 241,120.643 [DR 11]
Jun 281,206.714 [DR 12]
July 41,305.499 [DR 13]
July 141,414.609 [DR 14]
July 221,507.605 [DR 15]
July 281,601.249 [DR 16]
August 31,708.356 [DR 17]
August 101,808.092 [DR 18]
August 181,900.127 [DR 19]
August 262,003.914 [DR 20]

Vaccines

As of November 6, 2021, seven vaccines have been approved in mainland China through conditional marketing authorization or emergency use authorization.

VaccineTypeMade byOriginDose required for vaccinationEffective rate (Phase III)ApprovalDeploymentWHO Listed
Sinopharm BIBP Inactivated Beijing Institute of Biological ProductsChina2 doses [17] 78.1% [18] Green check.svg Conditional
(December 31, 2020) [19]
Green check.svg December 31, 2020Green check.svg May 7, 2021
CoronaVac Inactivated Sinovac Biotech China2 doses [17] 50.7% - 83.5% [20] [21] Green check.svg Conditional
(February 5, 2021) [22]
Green check.svg February 5, 2021Green check.svg June 1, 2021
Sinopharm WIBP Inactivated Wuhan Institute of Biological ProductsChina2 doses [17] 72.8% [18] Green check.svg Conditional
(February 25, 2021) [23]
Green check.svg February 25, 2021
KCONVAC Inactivated Kangtai Biological Products Co. Ltd.China2 doses [17] N/AGreen check.svg EUA
(May 14, 2021) [24]
Green check.svg June 1, 2021
Covidful Inactivated Institute of Medical Biology, Chinese Academy of Medical Sciences China2 doses [17] N/AGreen check.svg EUA
(June 9, 2021) [25]
Green check.svg June 9, 2021
Convidecia Viral vector CanSino China1 dose [17] 65.7% [26] Green check.svg Conditional
(February 25, 2021) [27]
Green check.svg February 25, 2021
ZIFIVAX Subunit Zhifei Bio-techChina3 doses [17] 82% [28] [29] Green check.svg EUA
(March 10, 2021) [30]
Green check.svg March 10, 2021

The Pfizer–BioNTech COVID-19 vaccine, agented by Fosun Pharma in mainland China, is waiting for approval. [31]

VaccineTypeMade byOriginDose required for vaccinationEffective rate (Phase III)ApprovalDeploymentWHO Listed
Comirnaty mRNA BioNTech and Fosun Pharma GermanyWaiting for Approval [31] Green check.svg December 31, 2020

Related Research Articles

Wu Zhen is a former Chinese politician who served as the Deputy Commissioner of the National Health and Family Planning Commission and the Deputy Director of the China Food and Drug Administration. He was dismissed from his position in August 2018 and placed under investigation by the Central Commission for Discipline Inspection and the National Supervisory Commission.

Timeline of the COVID-19 pandemic in January 2020 Sequence of major events in a virus pandemic

This article documents the chronology and epidemiology of SARS-CoV-2 in January 2020, the virus which causes the coronavirus disease 2019 (COVID-19) and is responsible for the COVID-19 pandemic. The first human cases of COVID-19 were identified in Wuhan, China, in December 2019.

COVID-19 pandemic in mainland China Ongoing COVID-19 viral pandemic in mainland China

The COVID-19 pandemic in mainland China is part of the worldwide pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). China was the first country to experience an outbreak of the disease, the first to impose drastic measures in response, and one of the first countries to bring the outbreak under control.

COVID-19 pandemic in Macau Ongoing COVID-19 viral pandemic in Macau

The COVID-19 pandemic in Macau is part of the ongoing worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. The first case of the disease in Macau was confirmed on 22 January 2020. The city saw nine more cases by 4 February, but no more cases until 15 March, when imported cases began to appear. Until 26 April 2021, the city has 49 cumulative confirmed cases of COVID-19, all of those having recovered, and no deaths from the disease. Stringent government measures have included the 15-day closure of all 81 casinos in the territory in February; in addition, effective 25 March, the territory disallowed connecting flights at its airport as well as entry by all non-residents, and from 6 April, the Hong Kong–Zhuhai–Macau Bridge was closed to public transport and most other traffic.

The COVID-19 pandemic in Hubei was first manifested by a cluster of mysterious pneumonia in Wuhan, the provincial capital of Hubei, China. A Wuhan hospital notified the local center for disease control and prevention (CDC) and health commissions on December 27, 2019. On December 31, Wuhan CDC admitted that there was a cluster of unknown pneumonia cases related to Huanan Seafood Wholesale Market after the unverified documents appeared on the Internet. The potential disease outbreak soon drew nationwide attention including that of the National Health Commission (NHC) in Beijing which sent experts to Wuhan on the following day. On January 8, a new coronavirus was identified as the cause of the pneumonia. The sequence of the virus was soon published on an open-access database. Measures taken by China have been controversial. They were praised by the World Health Organization (WHO) for improvements over SARS-CoV-2 responses, but maligned by many in the international community for being slow to publicly disclose key facts or deceptive about the outbreak and for aggressively censoring information relating to the outbreak and public discontent from citizens online.

COVID-19 pandemic in Shanghai Ongoing COVID-19 viral pandemic in Shanghai

The COVID-19 pandemic reached the city of Shanghai on 20 January 2020. As of 14 November 2020, 1,277 confirmed cases cumulatively occurred in the city, of which 934 cases were imported from abroad. Of the 96 active hospitalized cases ending at midnight, 94 were in stable condition and 1 was in critical condition; 1,174 had cumulatively recovered and been discharged, and 7 died.

The COVID-19 pandemic reached the province of Henan, China on 21 January 2020.

The COVID-19 pandemic reached the province of Sichuan, People's Republic of China on 20 January 2020, with its first case confirmed on the next day.

Zhang Wenhong Chinese doctor

Zhang Wenhong is a Chinese doctor, and a member of the Communist Party of China. He is the Director and Party Branch Secretary of the Department of Infectious Diseases at Huashan Hospital affiliated to Fudan University, the Director of the Internal Medicine Department of the Shanghai Medical College, and also the leader of the Shanghai Medical Treatment Experts Group, deputy director of the Shanghai Institute of Liver Diseases, and standing committee member of the Infectious Disease Branch of the Chinese Medical Association.

Zhang Jixian is a Chinese pulmonologist. She is known to have discovered SARS‑CoV‑2, and was the director of the Department of Respiratory Medicine of Hubei Provincial Hospital of Integrated Chinese & Western Medicine. She is also a member of the Chinese Communist Party.

Chang Shan-chwen Taiwanese medical researcher

Chang Shan-chwen is a Taiwanese medical researcher and academic administrator. He convenes the advisory specialist panel of the Central Epidemic Command Center (CECC), which is associated with the Centers for Disease Control in Taiwan. Chang Shan-chwen is vice president of National Taiwan University and professor of medicine in the university's medical college.

This article documents the situation of the COVID-19 pandemic in Inner Mongolia, the People's Republic of China.

The COVID-19 epidemic in Xinjiang Uyghur Autonomous Region is part of the worldwide pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). On 23 January 2020, the local government confirmed the first two case in Urumchi, the capital city of Xinjiang.

COVID-19 pandemic in Tibet Details of ongoing viral pandemic in the Tibet Autonomous Region

This article documents the situation of the COVID-19 pandemic in the Tibet Autonomous Region.

This article documents the situation of the COVID-19 pandemic in Liaoning Province, People's Republic of China.

This article documents the situation of the COVID-19 pandemic in the province of Heilongjiang, China. The first confirmed COVID-19 case in the province occurred in Mudanjiang on 21 January 2020, and though confirmed COVID-19 cases had begun to plateau by early March, by late March, international arrivals, largely from the neighboring Russian Far East, had added hundreds of cases to the province's total, leading to measures such as closed community management (封闭管理) in Suifenhe on 8 April.

COVID-19 pandemic in Beijing COVID-19 viral pandemic in Beijing, China

The COVID-19 pandemic reached the municipality of Beijing, China on 20 January 2020.

This article presents official statistics gathered during the COVID-19 pandemic in mainland China.

V-01 Vaccine candidate against COVID-19

V-01 is a COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group Inc.

COVID-19 vaccination in Taiwan Plan to immunize against COVID-19

COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 18 March 2021, vaccinations commenced on 22 March 2021, and will continue throughout the year with the goal of vaccinating 70% of the population by late October 2021.

References

Daily reports on COVID-19 vaccination
  1. National Health Commission (29 March 2021). "新冠病毒疫苗接种情况". Archived from the original on 30 March 2021. Retrieved 22 June 2021.
  2. National Health Commission (22 April 2021). "新冠病毒疫苗接种情况".
  3. National Health Commission (8 May 2021). "新冠病毒疫苗接种情况".
  4. National Health Commission (17 May 2021). "新冠病毒疫苗接种情况".
  5. National Health Commission (24 May 2021). "新冠病毒疫苗接种情况".
  6. National Health Commission (29 May 2021). "新冠病毒疫苗接种情况". Archived from the original on 30 May 2021. Retrieved 22 June 2021.
  7. National Health Commission (3 June 2021). "新冠病毒疫苗接种情况".
  8. National Health Commission (9 June 2021). "新冠病毒疫苗接种情况".
  9. National Health Commission (15 June 2021). "新冠病毒疫苗接种情况".
  10. National Health Commission (20 June 2021). "新冠病毒疫苗接种情况".
  11. National Health Commission (25 June 2021). "新冠病毒疫苗接种情况".
  12. National Health Commission (29 June 2021). "新冠病毒疫苗接种情况". Archived from the original on 30 June 2021. Retrieved 31 August 2021.
  13. National Health Commission (5 July 2021). "新冠病毒疫苗接种情况".
  14. National Health Commission (15 July 2021). "新冠病毒疫苗接种情况". Archived from the original on 16 July 2021. Retrieved 31 August 2021.
  15. National Health Commission (23 July 2021). "新冠病毒疫苗接种情况". Archived from the original on 24 July 2021. Retrieved 31 August 2021.
  16. National Health Commission (29 July 2021). "新冠病毒疫苗接种情况".
  17. National Health Commission (4 August 2021). "新冠病毒疫苗接种情况". Archived from the original on 5 August 2021. Retrieved 31 August 2021.
  18. National Health Commission (11 August 2021). "新冠病毒疫苗接种情况". Archived from the original on 12 August 2021. Retrieved 31 August 2021.
  19. National Health Commission (19 August 2021). "新冠病毒疫苗接种情况".
  20. National Health Commission (27 August 2021). "新冠病毒疫苗接种情况".
News and Articles
  1. 1 2 3 Ritchie, Hannah; Mathieu, Edouard; Rodés-Guirao, Lucas; Appel, Cameron; Giattino, Charlie; Ortiz-Ospina, Esteban; Hasell, Joe; Macdonald, Bobbie; Beltekian, Diana; Dattani, Saloni; Roser, Max (2020–2021). "Coronavirus Pandemic (COVID-19)". Our World in Data . Retrieved 28 November 2021.
  2. "中国于7月22日启动新冠疫苗紧急使用 接种人数超2万". Jiefang Daily . 23 August 2020. Archived from the original on 24 August 2020. Retrieved 2 April 2021.
  3. 1 2 陈席元; 徐鹏航 (20 June 2021). "十亿来之不易,你我仍需努力". Xinhua News Agency. Archived from the original on 24 June 2021. Retrieved 23 June 2021.
  4. 1 2 "目前累计已完成100多万剂次新冠疫苗紧急接种 未出现严重不良反应". SCIO . 19 December 2020. Archived from the original on 2 May 2021. Retrieved 2 April 2021.
  5. 1 2 "中国首度正式批准新冠疫苗上市 大规模接种或将迅速展开". BBC.com. Archived from the original on 31 December 2020. Retrieved 31 December 2020.
  6. "中国新冠疫苗全民免费提供,关于疫苗的最权威信息都在这". The Beijing News . Archived from the original on 12 January 2021. Retrieved 31 December 2020.
  7. 1 2 彭韵佳 王琳琳 (27 January 2021). "目前我国已接种新冠疫苗2276.7万剂次". Xinhua News Agency. Archived from the original on 3 June 2021. Retrieved 22 June 2021.
  8. "钟南山:中国疫苗接种率为3.56%,计划6月底达40%". Guancha.cn. Archived from the original on 23 April 2021. Retrieved 16 March 2021.
  9. "孙春兰出席全国新冠病毒疫苗接种工作电视电话会议并讲话". Xinhua. 22 March 2021. Archived from the original on 24 March 2021. Retrieved 27 April 2021 via the State Council.
  10. "中国今起开始日报冠病疫苗接种数量". Lianhe Zaobao . 24 March 2021. Archived from the original on 24 April 2021. Retrieved 25 March 2021.
  11. NHC Bureau of Disease Control and Prevention (29 March 2021). "新冠病毒疫苗接种技术指南(第一版)". National Health Commission. Retrieved 3 April 2021.
  12. "全国新冠疫苗接种超2亿剂次". Chinanews.com. Archived from the original on 23 April 2021. Retrieved 23 April 2021.
  13. "国家卫健委:5月至今新增境外输入确诊病例142例 必须加快推进新冠疫苗接种". People.com.cn. 14 May 2021. Archived from the original on 14 May 2021. Retrieved 14 May 2021.
  14. "权威快报|全国新冠疫苗接种剂次超10亿". Xinhuanet.com. Xinhua News Agency. 20 June 2021.
  15. 张曼玉 (10 February 2021). "全国累计报告接种新冠疫苗4052万剂次,现有本土确诊病例连续15天下降". China Youth Daily. Archived from the original on 28 June 2021. Retrieved 22 June 2021.
  16. 彭韵佳 王琳琳 (15 March 2021). "我国新冠疫苗接种已达6498万人次". Xinhua News Agency. Archived from the original on 23 April 2021. Retrieved 22 June 2021.
  17. 1 2 3 4 5 6 7 "新冠病毒疫苗接种问答来了!涉及34个关键问题". Chinanews.com. 1 April 2021. Archived from the original on 5 May 2021. Retrieved 2 April 2021.
  18. 1 2 Al Kaabi, Nawal; Zhang, Yuntao; Xia, Shengli; Yang, Yunkai; Al Qahtani, Manaf M.; Abdulrazzaq, Najiba; Al Nusair, Majed; Hassany, Mohamed; Jawad, Jaleela S. (26 May 2021). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial". JAMA. 326 (1): 35–45. doi: 10.1001/jama.2021.8565 . ISSN   0098-7484. PMC   8156175 . PMID   34037666.
  19. "大陸宣布首款新冠疫苗有條件上市 保護率近八成". UDN (in Chinese). 31 December 2020. Archived from the original on 28 June 2021. Retrieved 31 December 2020.
  20. Tanriover, Mine Durusu; Doğanay, Hamdi Levent; Akova, Murat; Güner, Hatice Rahmet; Azap, Alpay; Akhan, Sıla; et al. (8 July 2021). "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey". The Lancet. 398 (10296): 213–222. doi:10.1016/S0140-6736(21)01429-X. ISSN   0140-6736. PMC   8266301 . PMID   34246358.
  21. Toscano, Cristiana (29 April 2021). "Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine" (PDF). World Health Organization (WHO). Archived (PDF) from the original on 13 July 2021. Retrieved 31 August 2021.
  22. "China approves Sinovac vaccines for general public use". South China Morning Post. 6 February 2021. Archived from the original on 23 June 2021. Retrieved 23 June 2021.
  23. "国家药监局附条件批准国药中生武汉公司新型冠状病毒灭活疫苗(Vero细胞)注册申请". National Medical Products Administration . 25 February 2021. Archived from the original on 2 March 2021. Retrieved 25 February 2021.
  24. "深圳康泰生物新冠灭活疫苗被纳入紧急使用". Xinhuanet.com. 15 May 2021. Archived from the original on 15 May 2021. Retrieved 15 May 2021.
  25. UDN (9 June 2021). "中國大陸再有一新冠病毒滅活疫苗上市使用". UDN (in Chinese). Archived from the original on 10 June 2021. Retrieved 10 June 2021.
  26. "CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says". Reuters. 8 February 2021. Archived from the original on 24 March 2021. Retrieved 8 February 2021.
  27. "中国国家药监局附条件批准国药集团武汉和康希诺两公司新冠疫苗注册申请". Reuters . 6 February 2021. Archived from the original on 28 June 2021. Retrieved 23 June 2021.
  28. "New Chinese vaccine shows 82% effectiveness against serious Covid-19". The Straits Times. 27 August 2021. Archived from the original on 30 August 2021. Retrieved 30 August 2021.
  29. "Chinese three-shot vaccine nearly 82 per cent effective, says maker". South China Morning Post. 28 August 2021. Archived from the original on 30 August 2021. Retrieved 30 August 2021.
  30. "新冠疫苗|智飛生物與中科院微生物所合作研發產品獲批緊急使用". HK01 (in Chinese). 16 March 2021. Archived from the original on 3 May 2021. Retrieved 3 April 2021.
  31. 1 2 "直击复星医药股东大会:mRNA新冠疫苗审批进展成焦点". National Business Daily. 12 June 2021. Archived from the original on 24 June 2021. Retrieved 23 June 2021.

See also